Zymeworks Announces Participation in Upcoming Conferences

Rhea-AI Summary

Zymeworks (NASDAQ: ZYME) announced participation in upcoming investor and medical conferences in January 2026, including the ASCO Gastrointestinal Cancers Symposium (Jan 8–10, 2026) in San Francisco and the J.P. Morgan Annual Healthcare Conference (Jan 12–16, 2026).

At ASCO GI, Zymeworks will present a Trials-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma (Abstract TPS608) on Jan 9, 11:30 am–1:00 pm PT. A partner presentation will feature late-breaking data for HERIZON-GEA-01 (zanidatamab combinations) on Jan 8 (LBA285).

Management will hold a corporate presentation and one-on-one meetings at J.P. Morgan, with the corporate presentation scheduled for Jan 14, 2026 at 3:00 pm PT. Abstract release timings are Jan 5 at 2:00 pm PT (most abstracts) and late-breaking abstracts at presentation day 7:00 am PT.

News Market Reaction – ZYME

+4.46%

1 alert

+4.46% News Effect

On the day this news was published, ZYME gained 4.46%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ASCO GI dates: January 8–10, 2026 ZW251 session time: Jan 9, 11:30 am–1:00 pm PT ZW251 abstract number: TPS608 +5 more

8 metrics

ASCO GI dates January 8–10, 2026 ASCO Gastrointestinal Cancers Symposium timing

ZW251 session time Jan 9, 11:30 am–1:00 pm PT Trials in Progress Poster Session for ZW251 (TPS608)

ZW251 abstract number TPS608 Phase 1 ZW251 hepatocellular carcinoma study abstract ID

HERIZON-GEA-01 abstract LBA285 Late-breaking Phase 3 HERIZON-GEA-01 oral presentation ID

J.P. Morgan presentation time Jan 14, 2026 at 3:00 pm PT Corporate presentation at J.P. Morgan Healthcare Conference

Abstract release time Jan 5, 2026 at 2:00 pm PT General ASCO GI abstract release timing

Late-breaking release time 7:00 am PT Release time for late-breaking abstracts on presentation day

Previous close price $24.94 Price before this conference participation news

Market Reality Check

Price: $26.60 Vol: Volume 639,786 is well be...

low vol

$26.60 Last Close

Volume Volume 639,786 is well below the 20-day average of 1,810,723 (relative volume 0.35). low

Technical Trading above the 200-day MA of 14.91, with last price at 24.94.

Peers on Argus

Peers in Biotechnology showed mixed moves, from -5.24% (DNTH) to +2.55% (PGEN) a...

Peers in Biotechnology showed mixed moves, from -5.24% (DNTH) to +2.55% (PGEN) and +2.36% (NTLA), with others near flat, indicating stock-specific dynamics for ZYME rather than a broad sector swing.

Historical Context

5 past events · Latest: Dec 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 02	Conference participation	Positive	+4.5%	Announced ASCO GI and J.P. Morgan conference participation with partner data updates.
Nov 24	Investor conferences	Positive	+4.0%	Management attendance at Evercore and Citi healthcare investor conferences.
Nov 18	Leadership change	Neutral	-3.8%	Appointment of Acting CIO to manage future cash flows and asset strategy.
Nov 18	Strategic initiative	Positive	-3.8%	Strategic plan with substantial potential milestones and share repurchase authorization.
Nov 17	Phase 3 results	Positive	+29.1%	Positive Phase 3 HERIZON-GEA-01 topline results for Ziihera in HER2+ GEA.

Pattern Detected

Conference and clinical data updates have often coincided with positive moves, while strategic/organizational news showed negative divergence.

Recent Company History

Over the last few months, Zymeworks reported several milestones. Positive Phase 3 HERIZON-GEA-01 results for Ziihera in HER2+ GEA on Nov 17, 2025 saw a 29.05% gain. A strategic initiative with noted milestones and a $125.0M repurchase authorization on Nov 18, 2025 coincided with a -3.81% move. Subsequent governance and investment role changes the same day also aligned with that decline. Investor and conference participation updates on Nov 24 and Dec 2, 2025 were followed by gains of 4.04% and 4.46%, respectively, suggesting markets responded favorably to visibility and data-focused catalysts.

Market Pulse Summary

This announcement outlines Zymeworks’ participation in major 2026 events, including ASCO GI and a J....

Analysis

This announcement outlines Zymeworks’ participation in major 2026 events, including ASCO GI and a J.P. Morgan corporate presentation on Jan 14, 2026 at 3:00 pm PT. The ZW251 Phase 1 trial-in-progress poster and partner-led HERIZON-GEA-01 presentations highlight ongoing work in HER2-driven and liver cancers. Historically, clinical and conference updates, such as the positive Phase 3 HERIZON-GEA-01 results, have been important catalysts. Investors may watch for detailed efficacy, safety, and partnering updates from these forums.

Key Terms

antibody-drug conjugate, hepatocellular carcinoma, gastroesophageal adenocarcinoma, overall survival, +4 more

8 terms

antibody-drug conjugate medical

"a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

hepatocellular carcinoma medical

"antibody-drug conjugate for hepatocellular carcinoma at ASCO GI"

Hepatocellular carcinoma is the most common form of primary liver cancer, arising from the main functional cells of the liver. For investors it matters because its serious health impact drives demand for diagnostic tests, treatments and long-term care; progress in trials or approvals can change a drugmaker’s revenue outlook much like a successful product launch can reshape a company’s future.

gastroesophageal adenocarcinoma medical

"HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA)"

Gastroesophageal adenocarcinoma is a cancer that starts in the gland-like cells lining the lower part of the esophagus where it meets the stomach. Think of those lining cells as plants that have grown out of control and invaded nearby tissue. It matters to investors because its prevalence, survival outlook and available treatments drive demand for drugs, clinical trials, regulatory approvals and potential revenue for companies developing therapies or diagnostics.

overall survival medical

"Landmark analysis of overall survival (OS) by objective response"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

objective response medical

"overall survival (OS) by objective response in patients (pts)"

An objective response is a measurable, predefined improvement in a disease — typically a clear shrinkage or disappearance of tumors — observed during a clinical trial using set rules for assessment. Investors care because it provides concrete evidence that a treatment is having the intended effect, like a visible score change on a scoreboard, and can influence regulatory approval chances, future sales prospects, and the valuation of the company developing the therapy.

biliary tract cancer medical

"advanced HER2-positive biliary tract cancer (BTC): post hoc analysis"

Biliary tract cancer is a group of cancers that start in the bile ducts or gallbladder, the small channels and organ that carry and store the digestive fluid bile; think of it as a clogging, growing problem in a body's plumbing for digestion. For investors, it matters because diagnosis, treatment advances, or clinical trial results can rapidly affect the commercial outlook for drugs, medical devices, and related healthcare companies tied to testing, therapy sales, or reimbursement.

late-breaking abstract technical

"Type: Late-Breaking Abstract Oral Presentation Session"

A late-breaking abstract is a short summary of new clinical or scientific data submitted and accepted for presentation at a medical or scientific conference after the usual submission deadline. Investors watch these because they often contain fresh, potentially market-moving results—like seeing the final score of a game released just before kickoff—so they can change expectations about a drug’s safety, effectiveness, or commercial prospects.

phase 3 medical

"first results from the phase 3 HERIZON-GEA-01 study"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. Not financial advice.

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz

• Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI

• Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT)

VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences.

ASCO Gastrointestinal Cancers Symposium
January 8-10, 2026
San Francisco, CA

Zymeworks Presentation

Presentation Title	Authors	Presentation Details
ZW251 —A Phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).	Sreenivasa Chandana, Robin Kate Kelley, Richard Finn, Ecaterina E. Dumbrava, Masafumi Ikeda, John Hamm, Jaspreet Grewal, Martin Gutierrez, Yuta Maruki, Takako Eguchi Nakajima, Tatsuki Ikoma, Maggie Weinstein, Sabeen Mekan, Ghassan K.Abou-Alfa	Type: Trials in Progress Poster Session Session: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Date: Friday, Jan. 9, 11:30 am – 1:00 pm PT Abstract number: TPS608

Partner Presentations

Presentation Title	Authors	Presentation Details
Zanidatamab (zani) + chemotherapy (chemo) ± tislelizumab (tisle) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): first results from the phase 3 HERIZON-GEA-01 study	Elena Elimova, Sun Young Rha, Kohei Shitara, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall Tebbutt, Jaffer Ajani, Norhidayu Bt Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Ye Chen, Jonathan Grim, Lin Shen, on behalf of the HERIZON-GEA-01 study group	Type: Late-Breaking Abstract Oral Presentation Session: Oral Abstract Session A: Cancers of the Esophagus and Stomach Date: Thursday, Jan. 8, 8:57 – 9:07 am PT Abstract number: LBA285
Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): post hoc analysis of the HERIZON-BTC-01 trial	James J Harding, Jia Fan, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui-Chuan Sun, Teresa Macarulla, Feng Xie, Jean-Philippe Metges, Jie’er Ying, John Bridgewater, Harpreet Singh Wasan, Michel Pierre Ducreux, Zinan Bao, Phillip M Garfin, Douglas S Fuller, Parveen Jayia, Shubham Pant	Type: Poster Session Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Date: Friday, Jan. 9, 11:30 am – 1:00 pm PT Abstract number: 545

The majority of abstracts accepted to ASCO GI will be released at 2:00 pm PT/ 5:00 pm Eastern Time (ET) on January 5, 2026. Late-breaking abstracts will be released at 7:00 am PT / 10:00 am ET on their day of presentation at the Symposium and made publicly available online at that time.

J.P. Morgan Annual Healthcare Conference
January 12-16, 2026
San Francisco, CA

Zymeworks’ management will participate in one-on-one meetings and a corporate presentation on January 14, 2026, at 3:00 pm PT.

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Investor inquiries:

Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

FAQ

What will Zymeworks present about ZW251 at ASCO GI 2026 (ZYME)?

Zymeworks will present a Trials-in-Progress poster (TPS608) on ZW251 for hepatocellular carcinoma on Jan 9, 2026, 11:30 am–1:00 pm PT.

When is the Zymeworks corporate presentation at J.P. Morgan 2026 (ZYME)?

The corporate presentation is scheduled for Jan 14, 2026 at 3:00 pm PT during the J.P. Morgan Annual Healthcare Conference.

What late-breaking data involving Zymeworks assets will appear at ASCO GI 2026 (ZYME)?

A partner presentation will deliver late-breaking results from the HERIZON-GEA-01 phase 3 study (zanidatamab combinations) on Jan 8, 2026 (LBA285).

When will ASCO GI 2026 abstracts for Zymeworks be publicly released (ZYME)?

Most abstracts will be released Jan 5, 2026 at 2:00 pm PT; late-breaking abstracts are released at 7:00 am PT on their presentation day.

How can investors attend Zymeworks’ J.P. Morgan presentation (ZYME)?

Investors can attend one-on-one meetings and the corporate presentation in San Francisco; check investor relations for webcast or scheduling details.